CENCORA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 234.2 USD | +0.09% |
|
-2.56% | +14.04% |
| Mar. 28 | Walgreens Lowers Top End of Fiscal 2024 Earnings Outlook Following Second-Quarter Beat | MT |
| Mar. 28 | Walgreens Boots: reduction in annual targets | CF |
Financials (USD)
| Sales 2024 * | 292B | Sales 2025 * | 311B | Capitalization | 46.63B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.07B | Net income 2025 * | 2.18B | EV / Sales 2024 * | 0.17 x |
| Net Debt 2024 * | 1.81B | Net cash position 2025 * | 2.24B | EV / Sales 2025 * | 0.14 x |
| P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
20.5
x | Employees | 44,000 |
| Yield 2024 * |
0.87% | Yield 2025 * |
0.9% | Free-Float | 58.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cencora, Inc.
More recommendations
More press releases
More news
| 1 day | -0.70% | ||
| 1 week | -3.79% | ||
| Current month | -3.70% | ||
| 1 month | -1.55% | ||
| 3 months | +6.64% | ||
| 6 months | +23.82% | ||
| Current year | +13.94% |
1 week
233.10
241.22
1 month
233.10246.75
Current year
204.53246.75
1 year
163.37246.75
3 years
111.34246.75
5 years
70.55246.75
10 years
62.55246.75
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Collis
CEO | Chief Executive Officer | 62 | 93-12-31 |
James Cleary
DFI | Director of Finance/CFO | 61 | 15-01-31 |
Jennifer Dubas
CMP | Compliance Officer | - | 22-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kathleen Hyle
BRD | Director/Board Member | 65 | 10-05-12 |
| Director/Board Member | 74 | 08-09-24 | |
D. Mark Durcan
BRD | Director/Board Member | 62 | 15-09-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.85% | 2 M€ | +21.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 234.2 | +0.09% | 986,035 |
| 24-04-12 | 234 | -0.70% | 822,327 |
| 24-04-11 | 235.6 | -0.91% | 810,744 |
| 24-04-10 | 237.8 | -0.32% | 712,151 |
| 24-04-09 | 238.6 | -0.74% | 807,596 |
Delayed Quote Nyse, April 12, 2024 at 04:00 pm EDT
More quotes
Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).
Calendar
2024-05-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
234
USD
Average target price
253.1
USD
Spread / Average Target
+8.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.94% | 46.63B | |
| -0.87% | 189B | |
| -2.73% | 106B | |
| -3.55% | 67.94B | |
| +9.71% | 52.48B | |
| -3.43% | 38.9B | |
| +7.92% | 27.82B | |
| +3.97% | 26.97B | |
| +6.39% | 25.94B | |
| +2.28% | 25.58B |
- Stock Market
- Equities
- COR Stock
